Evidence map›Paper›PMID 31319183›Full record

ReviewClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2020

Phenotypes of Gastroesophageal Reflux Disease: Where Rome, Lyon, and Montreal Meet.

David A Katzka, John E Pandolfino, Peter J Kahrilas

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 6 pooled it
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 6 syntheses or guidelines pooled it, 146 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guidelines on optimizing the use of proton pump inhibitors: PPI stewardship.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023
    Guideline
  6. Pooled it
  7. Trial
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

David A KatzkaDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
John E PandolfinoDepartment of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Peter J KahrilasDepartment of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Electronic address: p-kahrilas@northwestern.edu.
Northwestern University · USMayo Clinic · US

Funding

Northwestern University Clinical and Translational Science Institute (NUCATS)UL1TR001422 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI D'AQUILA, RICHARD · 2015 to 2023
$56.8M
Role of altered response to volumetric distension in esophageal diseaseP01DK117824 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI PANDOLFINO, JOHN E · 2018 to 2022
$7.3M
Targeting Hypervigilance and Autonomic Arousal: the Psycho-physiologic Model of GERDR01DK092217 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI JOHN E PANDOLFINO · 2012 to 2026
$5.0M
NCATS NIH HHS UL1 TR001422NIDDK NIH HHS P01 DK117824NIDDK NIH HHS R01 DK092217
6 · The paper itself

Abstract

Gastroesophageal reflux disease (GERD) is now one of the most common diagnoses made in a gastroenterology practice. From a conventional pathophysiological perspective, GERD is conceptualized as incompetence of the antireflux barrier at the esophagogastric junction; the more severe that incompetence, the worse the disease. However, it is increasingly clear that many presentations of GERD represent distinct phenotypes with unique predisposing cofactors and pathophysiology outside of this paradigm. Three major consensus initiatives have grappled with this dilemma (the Montreal Consensus, The Rome Foundation, and the Lyon Consensus), each from a different perspective. Montreal struggled to define the disease, Rome sought to characterize its functional attributes, while Lyon examined its physiological attributes. Here, we merge the 3 perspectives, developing the concept that what has come to be known as GERD is actually a family of syndromes with a complex matrix of contributing pathophysiology. A corollary to this is that the concept of one size fits all to therapeutics does not apply, and that although escalating treatment with proton pump inhibitors (PPIs) may be pertinent to healing esophagitis, its applicability beyond that is highly questionable. Similarly, failing to recognize the modulating effects of anxiety, hypervigilance, and visceral and central hypersensitivity on symptom severity has greatly oversimplified the problem. That oversimplification has led to excessive use of PPIs for everything captured under the GERD umbrella and shown a broad spectrum of syndromes less amenable to PPI therapy in any dose. It is with this in mind that we delineate this precision medicine concept of GERD.

Indexed as

Gastroesophageal RefluxEsophagogastric JunctionHumansPhenotypeProton Pump InhibitorsRomeProton Pump InhibitorsBarrett's EsophagusEsophagitisEsophagusGastroesophageal Reflux DiseaseHiatus HerniaProton Pump Inhibitors

Identifiers

PMID31319183
PMCPMC6960363
OpenAlexW2958445840

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.